

WHOLE EXOME SOLUTION™ BY SOPHiA GENETICS

The molecular diagnostic application that bundles the analytical power of SOPHiA™ AI with a capture-based target enrichment kit and full to the SOPHiA DDM™ platform.



The WES panel covers the coding regions (\pm 5bp of intronic regions) of more than 19,000 RefSeq Genes and spans 39 Mb of target region. It guarantees high on-target reads percentage and coverage uniformity even in GC-rich regions, including the first exon.

Gene panel

> 19,000 genes

Recommendations

Starting material: 200 ng

Sample source: Blood

Samples per run: Depending on sequencing platform⁽¹⁾

Sequencer	Flow Cell / Sequencing Kit	Recommended samples per run (for 100x median coverage)
Illumina NextSeq® 500/550	Mid Output Kit v2 (2x150bp)	3
	High Output Kit v2 (2x150bp)	9
Illumina HiSeq® 2500	High Output (2x125bp)	6 (per lane)
	Rapid Run Mode (2x150bp)	3 (per lane)

Wet lab

Day 1: Library Preparation

Day 2: Capture and Sequencing

Total hands-on time: 8 hours

SOPHiA analyzes complex NGS data by detecting, annotating and pre-classifying genomic variants such as SNVs, Indels and CNVs⁽²⁾ to help clinicians better diagnose their patients. SOPHiA reaches excellent clinical-grade performance:

	Observed
Sensitivity	> 99% ⁽³⁾
Precision	> 99% ⁽³⁾
Reproducibility	> 99%
Average on-target rate	> 90%
Coverage uniformity	> 98%
Average % of target region with depth > 20x	> 99%

Analysis time from FASTQ files: Overnight⁽⁴⁾

All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them

(1) Sequencing recommendations and specifications for other sequencing kits and instruments available upon request

(2) The resolution of CNV detection, ranging from 2-5 exons, depends on the applied sequencing depth per sample. CNV detection is available for 92.2% of the WES genes (18,010 genes)

(3) Performance metrics are based on high confidence regions in a reference sample. Values have been calculated on a reference sample and 80 M reads per sample on a HiSeq® instrument (150bp read length)

(4) Analysis time may vary depending on the number of samples multiplexed and server load

The results are presented in SOPHiA DDM, the platform of choice for clinicians performing routine diagnostic testing. Thanks to its intuitive user interface and integrated features, variants visualization and interpretation are facilitated, while assuring protection of clinical genomic data.

Main features

Dedicated features in SOPHiA DDM reduce the complexity of determining the clinical significance of genomic variants.

- **Dual variant pre-classification:** Pre-classify variants according to both ACMG guidelines and SOPHiA's prediction to offer a comprehensive set of information to clinicians for improved assessment of variants pathogenicity.
- **Familial Variant Analysis (trio analysis):** Identify disease causing variants for different modes of inheritance, following a family-based approach
- **Virtual Panels:** Restrict the interpretation to sub-panels of genes of interest (e.g. intellectual disability or skeletal dysplasia) or according to patient's consent to prevent incidental findings
- **Variant Filter Builder:** Define and edit custom filters for efficient and dynamic analysis of exomes

Access to SOPHiA's Community

In SOPHiA DDM, experts from hundreds of healthcare institutions interpret the results and flag the pathogenicity level of variants in accordance to their knowledge. This highly valuable information feeds the variant knowledge base and is anonymously and safely shared among the members of the community.



SOPHiA™

The AI Democratizing Data-Driven Medicine

sophiagenetics.com | info@sophiagenetics.com | [@SOPHiAGENETICS](https://twitter.com/SOPHiAGENETICS)